Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine

Koichi Yokogawa, Tohru Nakaharu, Junko Ishizaki, Eijiro Ozaki, Yasuo Takeda, Hiroshi Mabuchi, Ryo Matsushita, Kazuko Kimura, Emi Nakashima, Fujio Ichimura, Ken Ichi Miyamoto

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We found that N-acetylation polymorphism can be evaluated from the disposition kinetics of sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA) and their acetylated metabolites generated by N-acetyltransferase (NAT2) after oral administration of salicylazosulfapyridine (SASP). In 126 Japanese subjects, the homozygote of NAT2*4 was the most frequent (40%), followed by heterozygotes of NAT2*4 and mutant genes (28% NAT2*4/*6A, 15% NAT2*4/*7B, and 2% NAT2*4/*5B). Combinations of mutant genes accounted for 16%. When the relationship between the molar ratio of N-acetyl-SP (Ac-SP)/SP or N-acetyl-5-ASA(Ac-5-ASA)/5-ASA in serum and five genotypes of polymorphic NAT2* was examined in patients who received multiple doses of SASP, the molar ratios of Ac-SP/SP, rather than Ac-5-ASA/5-ASA tended to decrease according to the classification of genotype. We calculated the pharmacokinetic parameters in healthy subjects with various genotypes of polymorphic NAT2* after a single p.o. administration of SASP, according to a model of the SP metabolic pathways. The molar ratios of Ac-SP/SP in serum and urine were simulated using these parameters, and the molar ratio of Ac-SP/SP in urine at 4 days after the first administration could be categorized into ranges that were specific to various NAT2* genotypes. Thus, we were able to predict the N-acetylation polymorphic genotypes of patients by measuring the molar ratio of Ac-SP/SP in urine, after administration of SASP.

Original languageEnglish
Pages (from-to)183-191
Number of pages9
JournalInternational Journal of Pharmaceutics
Volume229
Issue number1-2
DOIs
Publication statusPublished - 2001 Oct 28

Fingerprint

Sulfapyridine
Sulfasalazine
Acetylation
Mesalamine
Genotype
Urine
Acetyltransferases
Homozygote
Heterozygote
Metabolic Networks and Pathways
Serum
Genes
Oral Administration
Healthy Volunteers
Pharmacokinetics

Keywords

  • Genotype
  • NAT2*
  • Pharmacokinetics
  • Phenotype
  • Salicylazosulfapyridine

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine. / Yokogawa, Koichi; Nakaharu, Tohru; Ishizaki, Junko; Ozaki, Eijiro; Takeda, Yasuo; Mabuchi, Hiroshi; Matsushita, Ryo; Kimura, Kazuko; Nakashima, Emi; Ichimura, Fujio; Miyamoto, Ken Ichi.

In: International Journal of Pharmaceutics, Vol. 229, No. 1-2, 28.10.2001, p. 183-191.

Research output: Contribution to journalArticle

Yokogawa, K, Nakaharu, T, Ishizaki, J, Ozaki, E, Takeda, Y, Mabuchi, H, Matsushita, R, Kimura, K, Nakashima, E, Ichimura, F & Miyamoto, KI 2001, 'Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine', International Journal of Pharmaceutics, vol. 229, no. 1-2, pp. 183-191. https://doi.org/10.1016/S0378-5173(01)00864-X
Yokogawa, Koichi ; Nakaharu, Tohru ; Ishizaki, Junko ; Ozaki, Eijiro ; Takeda, Yasuo ; Mabuchi, Hiroshi ; Matsushita, Ryo ; Kimura, Kazuko ; Nakashima, Emi ; Ichimura, Fujio ; Miyamoto, Ken Ichi. / Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine. In: International Journal of Pharmaceutics. 2001 ; Vol. 229, No. 1-2. pp. 183-191.
@article{97b152c1a48f42e1a2b12bf9004e4738,
title = "Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine",
abstract = "We found that N-acetylation polymorphism can be evaluated from the disposition kinetics of sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA) and their acetylated metabolites generated by N-acetyltransferase (NAT2) after oral administration of salicylazosulfapyridine (SASP). In 126 Japanese subjects, the homozygote of NAT2*4 was the most frequent (40{\%}), followed by heterozygotes of NAT2*4 and mutant genes (28{\%} NAT2*4/*6A, 15{\%} NAT2*4/*7B, and 2{\%} NAT2*4/*5B). Combinations of mutant genes accounted for 16{\%}. When the relationship between the molar ratio of N-acetyl-SP (Ac-SP)/SP or N-acetyl-5-ASA(Ac-5-ASA)/5-ASA in serum and five genotypes of polymorphic NAT2* was examined in patients who received multiple doses of SASP, the molar ratios of Ac-SP/SP, rather than Ac-5-ASA/5-ASA tended to decrease according to the classification of genotype. We calculated the pharmacokinetic parameters in healthy subjects with various genotypes of polymorphic NAT2* after a single p.o. administration of SASP, according to a model of the SP metabolic pathways. The molar ratios of Ac-SP/SP in serum and urine were simulated using these parameters, and the molar ratio of Ac-SP/SP in urine at 4 days after the first administration could be categorized into ranges that were specific to various NAT2* genotypes. Thus, we were able to predict the N-acetylation polymorphic genotypes of patients by measuring the molar ratio of Ac-SP/SP in urine, after administration of SASP.",
keywords = "Genotype, NAT2*, Pharmacokinetics, Phenotype, Salicylazosulfapyridine",
author = "Koichi Yokogawa and Tohru Nakaharu and Junko Ishizaki and Eijiro Ozaki and Yasuo Takeda and Hiroshi Mabuchi and Ryo Matsushita and Kazuko Kimura and Emi Nakashima and Fujio Ichimura and Miyamoto, {Ken Ichi}",
year = "2001",
month = "10",
day = "28",
doi = "10.1016/S0378-5173(01)00864-X",
language = "English",
volume = "229",
pages = "183--191",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine

AU - Yokogawa, Koichi

AU - Nakaharu, Tohru

AU - Ishizaki, Junko

AU - Ozaki, Eijiro

AU - Takeda, Yasuo

AU - Mabuchi, Hiroshi

AU - Matsushita, Ryo

AU - Kimura, Kazuko

AU - Nakashima, Emi

AU - Ichimura, Fujio

AU - Miyamoto, Ken Ichi

PY - 2001/10/28

Y1 - 2001/10/28

N2 - We found that N-acetylation polymorphism can be evaluated from the disposition kinetics of sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA) and their acetylated metabolites generated by N-acetyltransferase (NAT2) after oral administration of salicylazosulfapyridine (SASP). In 126 Japanese subjects, the homozygote of NAT2*4 was the most frequent (40%), followed by heterozygotes of NAT2*4 and mutant genes (28% NAT2*4/*6A, 15% NAT2*4/*7B, and 2% NAT2*4/*5B). Combinations of mutant genes accounted for 16%. When the relationship between the molar ratio of N-acetyl-SP (Ac-SP)/SP or N-acetyl-5-ASA(Ac-5-ASA)/5-ASA in serum and five genotypes of polymorphic NAT2* was examined in patients who received multiple doses of SASP, the molar ratios of Ac-SP/SP, rather than Ac-5-ASA/5-ASA tended to decrease according to the classification of genotype. We calculated the pharmacokinetic parameters in healthy subjects with various genotypes of polymorphic NAT2* after a single p.o. administration of SASP, according to a model of the SP metabolic pathways. The molar ratios of Ac-SP/SP in serum and urine were simulated using these parameters, and the molar ratio of Ac-SP/SP in urine at 4 days after the first administration could be categorized into ranges that were specific to various NAT2* genotypes. Thus, we were able to predict the N-acetylation polymorphic genotypes of patients by measuring the molar ratio of Ac-SP/SP in urine, after administration of SASP.

AB - We found that N-acetylation polymorphism can be evaluated from the disposition kinetics of sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA) and their acetylated metabolites generated by N-acetyltransferase (NAT2) after oral administration of salicylazosulfapyridine (SASP). In 126 Japanese subjects, the homozygote of NAT2*4 was the most frequent (40%), followed by heterozygotes of NAT2*4 and mutant genes (28% NAT2*4/*6A, 15% NAT2*4/*7B, and 2% NAT2*4/*5B). Combinations of mutant genes accounted for 16%. When the relationship between the molar ratio of N-acetyl-SP (Ac-SP)/SP or N-acetyl-5-ASA(Ac-5-ASA)/5-ASA in serum and five genotypes of polymorphic NAT2* was examined in patients who received multiple doses of SASP, the molar ratios of Ac-SP/SP, rather than Ac-5-ASA/5-ASA tended to decrease according to the classification of genotype. We calculated the pharmacokinetic parameters in healthy subjects with various genotypes of polymorphic NAT2* after a single p.o. administration of SASP, according to a model of the SP metabolic pathways. The molar ratios of Ac-SP/SP in serum and urine were simulated using these parameters, and the molar ratio of Ac-SP/SP in urine at 4 days after the first administration could be categorized into ranges that were specific to various NAT2* genotypes. Thus, we were able to predict the N-acetylation polymorphic genotypes of patients by measuring the molar ratio of Ac-SP/SP in urine, after administration of SASP.

KW - Genotype

KW - NAT2

KW - Pharmacokinetics

KW - Phenotype

KW - Salicylazosulfapyridine

UR - http://www.scopus.com/inward/record.url?scp=0035965503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035965503&partnerID=8YFLogxK

U2 - 10.1016/S0378-5173(01)00864-X

DO - 10.1016/S0378-5173(01)00864-X

M3 - Article

C2 - 11604271

AN - SCOPUS:0035965503

VL - 229

SP - 183

EP - 191

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -